130 related articles for article (PubMed ID: 10362803)
1. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma.
Shin MS; Park WS; Kim SY; Kim HS; Kang SJ; Song KY; Park JY; Dong SM; Pi JH; Oh RR; Lee JY; Yoo NJ; Lee SH
Am J Pathol; 1999 Jun; 154(6):1785-91. PubMed ID: 10362803
[TBL] [Abstract][Full Text] [Related]
2. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer.
Lee SH; Shin MS; Park WS; Kim SY; Kim HS; Han JY; Park GS; Dong SM; Pi JH; Kim CS; Kim SH; Lee JY; Yoo NJ
Oncogene; 1999 Jun; 18(25):3754-60. PubMed ID: 10391683
[TBL] [Abstract][Full Text] [Related]
3. Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder.
Lee SH; Shin MS; Park WS; Kim SY; Dong SM; Pi JH; Lee HK; Kim HS; Jang JJ; Kim CS; Kim SH; Lee JY; Yoo NJ
Cancer Res; 1999 Jul; 59(13):3068-72. PubMed ID: 10397246
[TBL] [Abstract][Full Text] [Related]
4. Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer.
Boldrini L; Faviana P; Pistolesi F; Gisfredi S; Di Quirico D; Lucchi M; Mussi A; Angeletti CA; Baldinotti F; Fogli A; Simi P; Basolo F; Fontanini G
Oncogene; 2001 Oct; 20(45):6632-7. PubMed ID: 11641789
[TBL] [Abstract][Full Text] [Related]
5. Frequent deletion of Fas gene sequences encoding death and transmembrane domains in nasal natural killer/T-cell lymphoma.
Shen L; Liang AC; Lu L; Au WY; Kwong YL; Liang RH; Srivastava G
Am J Pathol; 2002 Dec; 161(6):2123-31. PubMed ID: 12466128
[TBL] [Abstract][Full Text] [Related]
6. Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scar.
Lee SH; Shin MS; Kim HS; Park WS; Kim SY; Jang JJ; Rhim KJ; Jang J; Lee HK; Park JY; Oh RR; Han SY; Lee JH; Lee JY; Yoo NJ
J Invest Dermatol; 2000 Jan; 114(1):122-6. PubMed ID: 10620127
[TBL] [Abstract][Full Text] [Related]
7. FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma.
Wohlfart S; Sebinger D; Gruber P; Buch J; Polgar D; Krupitza G; Rosner M; Hengstschläger M; Raderer M; Chott A; Müllauer L
Am J Pathol; 2004 Mar; 164(3):1081-9. PubMed ID: 14982861
[TBL] [Abstract][Full Text] [Related]
8. CDKN2A mutation and deletion status in thin and thick primary melanoma.
Cachia AR; Indsto JO; McLaren KM; Mann GJ; Arends MJ
Clin Cancer Res; 2000 Sep; 6(9):3511-5. PubMed ID: 10999737
[TBL] [Abstract][Full Text] [Related]
9. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma.
Lee SH; Shin MS; Lee HS; Bae JH; Lee HK; Kim HS; Kim SY; Jang JJ; Joo M; Kang YK; Park WS; Park JY; Oh RR; Han SY; Lee JH; Kim SH; Lee JY; Yoo NJ
Hum Pathol; 2001 Mar; 32(3):250-6. PubMed ID: 11274632
[TBL] [Abstract][Full Text] [Related]
10. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
Takahashi H; Feuerhake F; Kutok JL; Monti S; Dal Cin P; Neuberg D; Aster JC; Shipp MA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3265-71. PubMed ID: 16740746
[TBL] [Abstract][Full Text] [Related]
11. Frequent mutations of Fas gene in thyroid lymphoma.
Takakuwa T; Dong Z; Takayama H; Matsuzuka F; Nagata S; Aozasa K
Cancer Res; 2001 Feb; 61(4):1382-5. PubMed ID: 11245438
[TBL] [Abstract][Full Text] [Related]
12. Infrequent somatic Fas mutations but no evidence of Bcl10 mutations or t(11;18) in primary cutaneous MALT-type lymphoma.
Grønbaek K; Ralfkiaer E; Kalla J; Skovgaard GL; Guldberg P
J Pathol; 2003 Sep; 201(1):134-40. PubMed ID: 12950026
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of Fas resistance by Fas receptor mutation in a childhood B-precursor acute lymphoblastic leukemia cell line, MML-1.
Inaba H; Shimada K; Zhou YW; Ido M; Buck S; Yonehara S; Kaplan J; Komada Y
Int J Oncol; 2005 Aug; 27(2):573-9. PubMed ID: 16010441
[TBL] [Abstract][Full Text] [Related]
14. HLA-DR signaling inhibits Fas-mediated apoptosis in A375 melanoma cells.
Aoudjit F; Guo W; Gagnon-Houde JV; Castaigne JG; Alcaide-Loridan C; Charron D; Al-Daccak R
Exp Cell Res; 2004 Sep; 299(1):79-90. PubMed ID: 15302575
[TBL] [Abstract][Full Text] [Related]
15. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development.
Pollock PM; Welch J; Hayward NK
Cancer Res; 2001 Feb; 61(3):1154-61. PubMed ID: 11221846
[TBL] [Abstract][Full Text] [Related]
16. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.
Demunter A; Libbrecht L; Degreef H; De Wolf-Peeters C; van den Oord JJ
Mod Pathol; 2002 Apr; 15(4):454-61. PubMed ID: 11950921
[TBL] [Abstract][Full Text] [Related]
17. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.
Kumar R; Angelini S; Hemminki K
Oncogene; 2003 Dec; 22(58):9217-24. PubMed ID: 14681681
[TBL] [Abstract][Full Text] [Related]
18. Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin.
Dereure O; Levi E; Vonderheid EC; Kadin ME
J Invest Dermatol; 2002 Jun; 118(6):949-56. PubMed ID: 12060388
[TBL] [Abstract][Full Text] [Related]
19. Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis.
Zhang H; Sun XF; Synnerstad I; Rosdahl I
Cancer J; 2007; 13(4):233-7. PubMed ID: 17762757
[TBL] [Abstract][Full Text] [Related]
20. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
Shukuwa T; Katayama I; Koji T
Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
